Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical giant has far too much going its way. Analysts predict that the weight ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Citi reaffirmed its bullish view on Eli Lilly (NYSE:LLY) stock as it sees significant upside from orforglipron, the company’s once-daily oral obesity drug candidate.

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its ...